Evidentic — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Evidentic is a Berlin-based service provider that addresses a critical bottleneck in biopharmaceutical R&D: access to small quantities of licensed reference drugs. By purchasing approved medicines, aliquoting them into milligram quantities, and storing them under controlled conditions, Evidentic offers biotech companies, CROs, and academic researchers a reliable and rapid source for originator molecules. This service is particularly valuable for biosimilar developers and novel biologic creators who require the exact reference product for head-to-head analytical comparisons, batch variation studies, and critical quality attribute (CQA) assessments, ultimately aiming to reduce development timelines and costs.

Antibodies

Technology Platform

Aseptic aliquoting and cold-chain storage platform for licensed therapeutic molecules. Combines pharmaceutical wholesale licensing, sterile lab processes to divide clinical vials into small quantities (0.02mg-500mg), and monitored -70°C storage for long-term stability.

Opportunities

The rapid growth of the biosimilars market and continued expansion of novel biologic drug development create sustained demand for accessible reference products.

There is a significant opportunity to expand into providing characterized analytical data alongside the physical aliquots, creating a higher-value service.

Geographic expansion, particularly into key R&D hubs in North America and Asia, represents a major growth vector.

Risk Factors

The business is heavily dependent on maintaining complex pharmaceutical wholesaler licenses and complying with evolving drug diversion and repackaging regulations across different countries.

Supply chain vulnerabilities exist, as sourcing depends on the availability of originator drugs from manufacturers who may restrict distribution.

Competition could emerge from larger distributors or reagent companies replicating the model.

Competitive Landscape

Evidentic operates in a niche with few direct competitors offering small, aseptically aliquoted clinical-grade reference materials. Indirect competition comes from researchers attempting to source full vials directly from manufacturers or through standard pharmaceutical distributors, which is costly and inefficient. Larger life science reagent companies (e.g., Thermo Fisher, Merck) could potentially enter the space but currently focus on research-grade antibodies, not clinical formulations.

More companies in Biologics / Biosimilars →More companies in Germany →